Immune & inflammation · Tissue repair
A three-amino-acid fragment of alpha-MSH marketed for gut healing and inflammation, with no human clinical studies identified by the FDA.
Also known as: Lys-Pro-Val, alpha-MSH(11-13) fragment
Evidence passport
Last reviewed 2026-08-23
Most of this evidence comes from animals and cells
Clinical maturity: Preclinical only; no human studies identified
The curated record does not establish any studied route of administration. The FDA identified no human exposure data via any route, so no route — marketed or otherwise — is described here as evidence.
Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.
Discovery
Preclinical
Phase I
Phase II
Phase III
Approved
No human clinical studies identified in the FDA's 2026 compounding review.
The terminal three amino acids of alpha-MSH, an endogenous melanocortin peptide. Sold in the research market for gut and inflammatory claims.
This is as thin as it gets: cell and animal findings without a single human clinical study identified by the FDA. Marketing that presents KPV as a gut-healing therapy is running years ahead of the evidence.
Animal and cell findings are Level 1–2 evidence.
No established human signal
No FDA-approved product exists. FDA material published for the 2026 compounding review states that the FDA identified no clinical studies or human exposure data for KPV via any route, and that human safety risks are unknown.
Cell, receptor or computational work explaining how something could work.
Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.
No recorded changes yet. Baseline position set on 2026-08-23.
Unsupported — the FDA identified no human studies at all.